Page 133 - 《中国药房》2023年16期

effects of anlotinib combined with oral 5-fluorouracil/S-1 AZD2811 monotherapy in relapsed small cell lung cancer
via inhibiting Src/AKT signaling pathway in small-cell [J]. J Clin Oncol，2019，37（15_suppl）：8514.
lung cancer[J]. Anal Cell Pathol，2022，2022：4484211. [28] KE Z Y，LIANG A L，LIU Y J. Cell cycle checkpoint ki‐
[14] 郭家毓，呼群. 小细胞肺癌免疫治疗研究进展[J]. 陕西医 nase and drug resistance of lung cancer[J]. Zhongguo Fei
学杂志，2023，52（1）：118-121. Ai Za Zhi，2021，24（4）：265-270.
[15] ROTTENBERG S，DISLER C，PEREGO P. The redisco- [29] 葛凡，孙建，黄璐. 小分子周期蛋白依赖性激酶4/6抑制
very of platinum-based cancer therapy[J]. Nat Rev Cancer， 剂药物及其专利研究[J]. 中国医药工业杂志，2022，53
2021，21（1）：37-50. （4）：464-473.
[16] PILIÉ P G，TANG C，MILLS G B，et al. State-of-the-art [30] LEONETTI A，FACCHINETTI F，MINARI R，et al.
strategies for targeting the DNA damage response in can‐ Notch pathway in small-cell lung cancer：from preclinical
cer[J]. Nat Rev Clin Oncol，2019，16（2）：81-104. evidence to therapeutic challenges[J]. Cell Oncol，2019，42
[17] BYERS L A，WANG J，NILSSON M B，et al. Proteomic （3）：261-273.
profiling identifies dysregulated pathways in small cell [31] GIFFIN M J，COOKE K，LOBENHOFER E K，et al.
lung cancer and novel therapeutic targets including PARP1 AMG 757，a half-life extended，DLL3-targeted bispecific
[J]. Cancer Discov，2012，2（9）：798-811. T-cell engager，shows high potency and sensitivity in pre‐
[18] SEN T，TONG P，STEWART C A，et al. CHK1 inhibition clinical models of small-cell lung cancer[J]. Clin Cancer
in small-cell lung cancer produces single-agent activity in Res，2021，27（5）：1526-1537.
biomarker-defined disease subsets and combination acti- [32] ZHAN J B，HAN Q，WANG K Y. Development of anti‐
vity with cisplatin or olaparib[J]. Cancer Res，2017，77 body therapeutics for small cell lung cancer[J]. Expert
（14）：3870-3884. Opin Investig Drugs，2013，22（2）：235-244.
[19] HENDRIKS L E L，MENIS J，RECK M. Prospects of tar‐ [33] BREZICKA T，BERGMAN B，OLLING S，et al. Reacti-
geted and immune therapies in SCLC[J]. Expert Rev Anti‐ vity of monoclonal antibodies with ganglioside antigens in
cancer Ther，2019，19（2）：151-167. human small cell lung cancer tissues[J]. Lung Cancer，
[20] SOS M L，DIETLEIN F，PEIFER M，et al. A framework 2000，28（1）：29-36.
for identification of actionable cancer genome dependen‐ [34] CHU Q，LEIGHL N B，SURMONT V，et al. BMS-
cies in small cell lung cancer[J]. Proc Natl Acad Sci U S 986012，an anti-fucosyl-GM1 monoclonal antibody as
A，2012，109（42）：17034-17039. monotherapy or in combination with nivolumab in re‐
[21] SERZAN M T，FARID S，LIU S V. Drugs in development lapsed/refractory SCLC：results from a first-in-human
for small cell lung cancer[J]. J Thorac Dis，2020，12（10）： phase 1/2 study[J]. JTO Clin Res Rep，2022，3（11）：
6298-6307. 100400.
[22] HERZOG B H，DEVARAKONDA S，GOVINDAN R. [35] 谢君鸿，何晶晶，周鹏辉. 合成生物学与工程化T细胞治
Overcoming chemotherapy resistance in SCLC[J]. J Tho‐ 疗[J]. 合成生物学，2023，4（2）：373-393.
rac Oncol，2021，16（12）：2002-2015. [36] WALIA H K，SHARMA P，SINGH N，et al. Immuno‐
[23] PIETANZA M C，WAQAR S N，KRUG L M，et al. Ran‐ therapy in small cell lung cancer treatment：a promising
domized，double-blind，phase Ⅱ study of temozolomide headway for future perspective[J]. Curr Treat Options On‐
in combination with either veliparib or placebo in patients col，2022，23（2）：268-294.
with relapsed-sensitive or refractory small-cell lung cancer [37] BIANCO A，D’AGNANO V，MATERA M G，et al. Im‐
[J]. J Clin Oncol，2018，36（23）：2386-2394. mune checkpoint inhibitors：a new landscape for extensive
[24] MURAI J，TANG S W，LEO E，et al. SLFN11 blocks stage small cell lung cancer treatment[J]. Expert Rev
stressed replication Forks independently of ATR[J]. Mol Respir Med，2021，15（11）：1415-1425.
Cell，2018，69（3）：371-384. [38] 戢福云，钱桂生，钱频，等. bcl-2对人小细胞肺癌细胞系
[25] SEN T，RODRIGUEZ B L，CHEN L M，et al. Targeting H446/DDP多药耐药性的影响[J]. 中华结核和呼吸杂志，
DNA damage response promotes antitumor immunity 2006，29（3）：156-160.
through STING-mediated T-cell activation in small cell [39] LAKHANI N J，RASCO D W，ZENG Q，et al. First-in-
lung cancer[J]. Cancer Discov，2019，9（5）：646-661. human study of palcitoclax（APG-1252），a novel dual Bcl-
[26] SEN T，TONG P，DIAO L X，et al. Targeting AXL and 2/Bcl-xL inhibitor，demonstrated advantages in platelet
mTOR pathway overcomes primary and acquired resis‐ safety while maintaining anticancer effect in US patients
tance to WEE1 inhibition in small-cell lung cancer[J]. with metastatic solid tumors[EB/OL]. [2023-02-10].
Clin Cancer Res，2017，23（20）：6239-6253. http：//www.mhn24.com/7673.html.
[27] PARK S，SHIM J，JUNG H，et al. Biomarker driven phase （收稿日期：2023-02-28 修回日期：2023-07-24）
Ⅱ umbrella trial study of AZD1775， AZD2014， （编辑：邹丽娟）

中国药房 2023年第34卷第16期 China Pharmacy 2023 Vol. 34 No. 16 · 2043 ·